Cann Global Ltd. provides the following update in relation to CGB's Nutraceutical manufacturing schedule and the Israeli based Pharmocann formulator's visit to Australia. CGB has a 50/50 partnership agreement with one of Israel's leading Cannabis companies Pharmocann, to produce and sell Pharmocann's unique advanced cannabis-based treatment [...]
The suspension of trading in the securities of Cann Global Ltd. is expected to lift and the Company reinstated to official quotation at the commencement of trading on Friday 23 August 2019, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. The Company raised $5,950,000 pursuant to the offer under its replacement prospectus [...]
Cann Global Ltd. provides the following update in connection with the reinstatement to quotation of the Company's fully paid Ordinary Shares. The Company is pleased to announce that the ASX have received confirmation that the final documents are now en route via courier from overseas. Upon receipt of these documents by the ASX to satisfy the [...]
Cann Global Ltd. provides the following update in connection with the reinstatement to quotation of the Company's fully paid Ordinary Shares. Upon release of this information to the market, and subject to the receipt by ASX of certain original documents being couriered from overseas, CGB anticipates that its securities will be reinstated to trading [...]
As foreshadowed in the Company's announcement dated 15 May 2019, Cann Global Limted confirms that the appointments of David Austin, Jonathan Cohen and John Easterling as independent directors took effect upon approval by Shareholders at the 2 July 2019 General Meeting. The various non-executive independent Directors will be responsible to enhance [...]
Cann Global Ltd. is pleased to advise that the company is in the process of providing the ASX with all the paperwork confirming completion of all the transactions, completion of all the share issues, receipt of all the required escrow agreements, and the related required relisting documentation. The Company is now finalising the various share [...]
Queensland Bauxite Ltd. is most pleased to announce that the Company has received the formal approval letter for its application for reinstatement to the official list of ASX Limited . The Company's securities are to be reinstated to official quotation on a date to be decided by ASX but not before 25 January 2019, subject to compliance with the [...]
Queensland Bauxite Ltd. provides the Company's cover note and second supplementary prospectus. This attached second supplementary prospectus has included updated information on the original prospectus that was lodged with the ASIC on 27 September 2018 and the first supplementary prospectus lodged with the ASIC on 17th October 2018. The Company is [...]
The Board of Queensland Bauxite Ltd. is very pleased to announce a materially strategic transaction, that its soon to be wholly owned subsidiary Medcan Australia, has entered into a Strategic Collaboration and Supply Agreement Signed with an established Canadian Licensed Producer of Medical Cannabis. As a result of a relationship forged over the [...]
Queensland Bauxite Ltd. provides the Company's Annual Report to shareholders. EXECUTIVE CHAIRPERSON'S LETTER Dear Shareholders, "This is just the beginning" - December 2017 Quarterly Report What a significant year it has been for the company and our loyal shareholders. This letter begins by quoting the phrase I used in the QBL December 2017 [...]
The Board of Queensland Bauxite Ltd. is very pleased to announce a materially strategic transaction, that its soon to be wholly owned subsidiary Medcan Australia, has entered into a memorandum of understanding with top Israeli medicinal cannabis company Pharmocann. Pharmocann is recognised as being amongst the world's foremost and experienced [...]